Inhibitors of topoisomerase II, such as doxorubicin, are effective chemotherapy for multiple myeloma.
Resistance to these agents may arise when cancer cells export topoisomerase II alpha from the nucleus to the cytoplasm.
Scientists at Moffitt Cancer Center have identified small molecules that inhibit nuclear export of topoisomerase II alpha and sensitize human myeloma cells to topoisomerase II inhibitors such as doxorubicin.
These newly identified export inhibitors may be useful as agents for treating multiple myeloma and other hematologic cancers, either alone or in combination with topoisomerase II inhibitors.
Resistance to these agents may arise when cancer cells export topoisomerase II alpha from the nucleus to the cytoplasm.
Scientists at Moffitt Cancer Center have identified small molecules that inhibit nuclear export of topoisomerase II alpha and sensitize human myeloma cells to topoisomerase II inhibitors such as doxorubicin.
These newly identified export inhibitors may be useful as agents for treating multiple myeloma and other hematologic cancers, either alone or in combination with topoisomerase II inhibitors.
Contact
Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596
08MB014 10MB078
